http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0700446-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_181fbca0c88a7079896b6c749d92e215 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 |
| filingDate | 2007-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6968156aeff59c3dc5e32e97e84d4f4f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e05382f51ad20b008929c35434932006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f61923dd02ca4fb28a4a2f85bb839b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f88a7356ec02890a14cb282016aa9a0d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdd92d4ffb198ae303474cdcb6ba97a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67c2dcd2614b3d7e6e74aed099fbb5ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9e9f6fac3ce8af621a62bd9fe04ea4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df5b5c7c6fad3309cb3b4656571b98f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ba9e57e05095aabf9c162766ee9357e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6a0c157e1c0edbd09c4b5af56fe318d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93d441c9b46202682eb2c51d894a98c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_241b0a150049d61e712ec0e8904b7f5e |
| publicationDate | 2008-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0700446-A2 |
| titleOfInvention | nanoencapsulated formulation of amphotericin b drug with dimercaptosuccinic acid in polylactic polyglycolic acid polymer for the treatment of mycoses |
| abstract | NANOENCAPSULATED FORMULATION OF DRUG AMPHOTYCIN B WITH DIMERCAPTOSUCCINIC ACID IN POLYLATIC POLYLICYLIC ACID POLYMER FOR TREATMENT OF MICROSES. Idealized from the composition of elements consisting of nano and microparticulate systems prepared from a blend of polylactic-polyglycolic derived polymers, in the proportions of 15 to 75% polylactic and 15 to 75% polyglycolic derivative in blend, initially dissolved in a volume of 5 to 10m1 of dichloromethane, in the total amount of 50 to 150mg of final blended spray. The first emulsification (water / oil) contains amphotericin B in a concentration of 60 to 120 mg. The formulation contains in its composition dimercaptosuccinic acid (in the concentration range 0.01 to 0.1M), which acts as a preferential carrier for the lungs, which decreases the high serum levels of the drug in order to reduce the side effects caused by same during the treatment of lung infections and also other organs. Therefore, in the patent application in question, as a drug, nanostructured and microstructured amphotericin B is specially designed and developed to obtain enormous practicality and brings great advantages, both in its use and in its manufacture, adding low costs for its use. industrial feasibility, but allied to the antiseptic requirements of healthiness and utility practicality, thus offering the consumer public an additional option in the market of counterparts, which unlike the usual substances applied in the treatment of mycoses, offers numerous possibilities and benefits to patients as the total absence of frequent side effects in other forms of treatment becoming a product of wide acceptance in the drug-therapeutic market. |
| priorityDate | 2007-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.